Single-dose Intravitreal Bevacizumab after complete panretinal photocoagulation in Proliferative Diabetic Retinopathy: An Effective Adjunctive Treatment

Alireza Dehghani, Heshmatollah Ghanbari, Abdolsamad Mahdizadeh, Mohsen Pourazizi


Patients with Proliferative Diabetic Retinopathy (PDR) who were refractory to complete panretinal photocoagulation (PRP) have a high risk of severe vision loss. The aim of this study is evaluation of single-dose intravitreal bevacizumab (IVB) after complete PRP in refractory PDR subjects.

Patients with retinal neovascularization (NV) secondary to diabetes mellitus and refractory to complete PRP enrolled the study. All Patients received single dose of 1.25 mg IVB three months after complete the PRP. Patients underwent complete ophthalmic evaluation and fluorescein angiography (FA) at baseline and one month after injection. The main outcome described as reduction in the areas of leakage (mm2) found in the FA. All patients were evaluated at baseline and on every visit at 1 day, 1 weeks and 1 month.

A total of 21 consecutive patients (32 eyes) with PDR, were enrolled completed this study. Thirteen (61.9%) was female. The mean ± SD age was 64.1 ± 5.6years. Complete and Partial response of angiographic leakage of NV was noted in 7 (21.9%) and 18 (56.2%) of 32 eyes after single injection respectively. No satisfactory response of retinal NV was observed in7 eyes (21.9%), one month after the injection. There is significant different regarding Mean ± SD age between response groups (Partial and complete; 61.9 ± 4.4) versus no satisfactory response group (67.7 ± 5.9) (p=0.007). No significant ocular or systemic adverse events were observed.

Base on our findings, it seems that single-dose of IVB could be associated with a satisfactory response of retinal NV secondary to PDR in subjects that refractory to complete PRP.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.